Imaging Techniques Used in the Diagnosis, Staging, and Follow-up of Patients with Myeloma

References

• Alexandrakis M., Kyriakou D., Passam F., Malliaraki N., Christophoridou A., Karkavitsas N. Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. Clin Lab Haematol 2002; 24: 155–9
   PubMedGoogle Scholar
• Alexanian R., Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–9
   PubMed Web of Science ®Google Scholar
• Angtuaco E., Fassas A., Walker R., Sethi R., Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231: 11–23
   PubMed Web of Science ®Google Scholar
• Baur A., Stabler A., Nagel D., Lamerz R., Bartl R., Hiller E., et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?. Cancer 2002; 95: 1334–45
   PubMed Web of Science ®Google Scholar
• Buhmann S., Baur-Melnyk A., Wieser A., Reiser M. Diagnostics of multiple myeloma using a 16-row-MSCT: low-dose whole body protocol. European Congress of Radiology March 2005
   Google Scholar
• Chen-Kiang S. Plasma cells and multiple myeloma. Immunol Rev 2003; 194: 5–7
   Web of Science ®Google Scholar
• Durie B., Kyle R., Belch A., Bensinger W., Blade J., Boccadoro M., et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–98
   PubMedGoogle Scholar
• Durie B., Waxman A., D'Agnolo A., Williams C. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–63
   PubMed Web of Science ®Google Scholar
• Durie B., Salmon S. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–54
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R., Gonzalez-Fraile M., Mateo G., Hernandez J., Lopez-Berges M., de las Heras N., et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004; 112: 884–9
   PubMed Web of Science ®Google Scholar
• Hargaden G., O'Connell M., Kavanagh E., Powell T., Ward R., Eustace S. Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging. Am J Roentgenol 2003; 180: 247–52
   PubMed Web of Science ®Google Scholar
• Hartman R., Sundaram M., Okuno S., Sim F. Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings. Am J Roentgenol 2004; 183: 645–53
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–57
   PubMed Web of Science ®Google Scholar
• Jadvar H., Conti P. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002; 31: 690–4
   PubMed Web of Science ®Google Scholar
• Kyle R., Gertz M., Witzig T., Lust J., Lacy M., Dispenzieri A., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Kyle R., Rajkumar S. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003; 194: 112–39
   PubMed Web of Science ®Google Scholar
• Lacy M., Gertz M., Hanson C., Inwards D., Kyle R. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 1997; 56: 288–93
   PubMed Web of Science ®Google Scholar
• Lecouvet F., Dechambre S., Malghem J., Ferrant A., Vande Berg B., Maldague B. Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging. Am J Roentgenol 2001; 176: 91–6
   PubMed Web of Science ®Google Scholar
• Lecouvet F., Malghem J., Michaux L., Maldague B., Ferrant A., Michaux J., et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999; 106: 35–9
   PubMed Web of Science ®Google Scholar
• Mahnken A., Wildberger J., Gehbauer G., Schmitz-Rode T., Blaum T., Fabry U., et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. Am J Roentgenol 2002; 178: 1429–36
   PubMed Web of Science ®Google Scholar
• Mendenhall W., Mendenhall C., Mendenhall N. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol 2003; 24: 395–9
   PubMed Web of Science ®Google Scholar
• Mileshkin L., Blum R., Seymour J., Patrikeos A., Hicks R., Prince H. A comparison of FDG PET and Tc-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004; 72: 32–7
   PubMed Web of Science ®Google Scholar
• Miralles G., O'Fallon J., Talley N. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992; 327: 1919–23
   PubMed Web of Science ®Google Scholar
• Moulopoulos L., Dimopoulos M., Weber D., Fuller L., Libshitz H., Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993; 11: 1311–15
   PubMed Web of Science ®Google Scholar
• Mulleman D., Gaxatte C., Guillerm G., Leroy X., Cotton A., Duquesnoy B., et al. Multiple myeloma presenting with widespread osteosclerotic lesions. Joint Bone Spine 2004; 71: 79–83
   PubMed Web of Science ®Google Scholar
• Mulligan M. Myeloma and lymphoma. Semin Musculoskelet Radiol 2000; 4: 127–35
   PubMedGoogle Scholar
• Schirrmeister H., Buck A., Bergmann L., Reske S., Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003; 18: 841–5
   PubMed Web of Science ®Google Scholar
• Sirohi B., Powles R. Multiple myeloma. Lancet 2004; 363: 875–7
   PubMed Web of Science ®Google Scholar
• Sohn S., Ahn B., Lee S., Kim D., Chun K., Kim J., et al. Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma. Eur J Nucl Med Mol Imaging 2002; 29: 591–6
   PubMed Web of Science ®Google Scholar
• Tricot G., Barlogie B., Jagannath S., Bracy D., Mattox S., Vesole D., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–56
   PubMed Web of Science ®Google Scholar
• Tsang R., Gospodarowicz M., Pintilie M., Bezjak A., Wells W., Hodgson D., et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001; 50: 113–20
   PubMed Web of Science ®Google Scholar
• Weber D., Dimopoulos M., Moulopoulos L., Delasalle K., Smith T., Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997; 97: 810–14
   PubMed Web of Science ®Google Scholar